Dulaglutide Injection Suppliers & Bulk Manufacturers
Available Forms: Prefilled Pens
Available Strengths: 0.75 mg/0.5 mL,1.5 mg/0.5 mL, 3.0 mg/0.5 mL, 4.5 mg/0.5 mL
Reference Brands: Trulicity®(US & EU)
Category:
Diabetes
Dulaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. Benefits include improved glycemic control in type 2 diabetes, weight reduction, and cardiovascular risk reduction in high-risk patients. Administered once weekly for convenience.
Dulaglutide Injection is available in Prefilled Pens
and strengths such as 0.75 mg/0.5 mL,1.5 mg/0.5 mL, 3.0 mg/0.5 mL, 4.5 mg/0.5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Dulaglutide Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Dulaglutide Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Dulaglutide is manufactured under cGMP (FDA) and GMP (EMA) standards, ensuring quality across production. The FDA approves Trulicity® for T2DM with cardiovascular risk reduction, requiring post-marketing safety monitoring (e.g., pancreatitis, thyroid C-cell tumors). The EMA mandates similar vigilance, including risk minimization for medullary thyroid carcinoma. Both agencies require sterile manufacturing, stability testing (refrigerated storage; 14-day room-temperature stability post-opening), and batch traceability. FDA’s REMS is not required, but EMA emphasizes patient education on injection techniques. Non-compliance risks include regulatory actions (warning letters, recalls). For compliant global sourcing, refer PharmaTradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing